Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01806324 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects
A Phase 1 study, sponsored by HanAll BioPharma Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01806324 is a Phase 1 study that has completed, run by HanAll BioPharma Co.. The registered enrollment target is 30 participants.
The verdict
NCT01806324, a Phase 1 study, has completed, sponsored by HanAll BioPharma Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study is: To evaluate the pharmacokinetics and safety of an experimental combination tablet containing 20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to healthy male subjects, compared with the concomitant administration of 20 mg atorvastatin and 50 mg losartan potassium tablets.
Interventions
- DRUG HL040XC
- DRUG Losartan + Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2012-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01806324
The ClinicalTrials.gov registry entry for NCT01806324 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HanAll BioPharma Co., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HL040XC is the first listed.
NCT01806324 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01806324 about?
NCT01806324 is a clinical study titled "A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects". The objective of this study is: To evaluate the pharmacokinetics and safety of an experimental combination tablet containing 20 mg atorvastatin and 50 mg losartan potassium when administered orally as a single dose to healthy male subjects, compared with the concomitant administration of 20 mg ator...
What is the current status of trial NCT01806324?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2012-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01806324?
The interventions under investigation include: HL040XC (DRUG), Losartan + Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT01806324?
This trial is sponsored by HanAll BioPharma Co., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.